Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.

Shu L, Sulaiman AH, Huang YS, Fones Soon Leng C, Crutel VS, Kim YS.

Asian J Psychiatr. 2014 Apr;8:26-32. doi: 10.1016/j.ajp.2013.09.009. Epub 2013 Sep 30.

PMID:
24655622
2.

Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.

Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V.

Int Clin Psychopharmacol. 2010 Nov;25(6):305-14. doi: 10.1097/YIC.0b013e32833a86aa.

PMID:
20856123
3.

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Baylé FJ.

J Clin Psychiatry. 2010 Feb;71(2):109-20. doi: 10.4088/JCP.09m05347blu.

PMID:
20193645
4.
5.

Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.

Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A.

J Clin Psychopharmacol. 2010 Apr;30(2):135-44. doi: 10.1097/JCP.0b013e3181d420a7.

PMID:
20520286
6.

A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.

Demyttenaere K, Corruble E, Hale A, Quera-Salva MA, Picarel-Blanchot F, Kasper S.

CNS Spectr. 2013 Jun;18(3):163-70. doi: 10.1017/S1092852913000060. Epub 2013 Mar 11.

PMID:
23472671
7.

Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months.

Kennedy SH, Avedisova A, Belaïdi C, Picarel-Blanchot F, de Bodinat C.

Eur Neuropsychopharmacol. 2016 Feb;26(2):378-89. doi: 10.1016/j.euroneuro.2015.09.006. Epub 2015 Sep 25.

PMID:
26708320
8.

Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.

Olié JP, Kasper S.

Int J Neuropsychopharmacol. 2007 Oct;10(5):661-73. Epub 2007 May 4.

PMID:
17477888
9.

The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study.

Heun R, Ahokas A, Boyer P, Giménez-Montesinos N, Pontes-Soares F, Olivier V; Agomelatine Study Group..

J Clin Psychiatry. 2013 Jun;74(6):587-94. doi: 10.4088/JCP.12m08250.

PMID:
23842010
10.

Agomelatine: efficacy at each phase of antidepressant treatment.

Kennedy SH.

CNS Drugs. 2009;23 Suppl 2:41-7. doi: 10.2165/11318660-000000000-00000. Review.

PMID:
19708725
11.

Double-blind comparison of bupropion and fluoxetine in depressed outpatients.

Feighner JP, Gardner EA, Johnston JA, Batey SR, Khayrallah MA, Ascher JA, Lineberry CG.

J Clin Psychiatry. 1991 Aug;52(8):329-35.

PMID:
1907963
14.

Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.

Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ; Comparative Efficacy Antidepressants Study Group..

CNS Drugs. 2005;19(2):137-46.

PMID:
15697327
15.

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA.

J Clin Psychiatry. 2002 Mar;63(3):225-31.

PMID:
11926722
16.

A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.

Kennedy SH, Avedisova A, Giménez-Montesinos N, Belaïdi C, de Bodinat C; Agomelatine Study Group..

Eur Neuropsychopharmacol. 2014 Apr;24(4):553-63. doi: 10.1016/j.euroneuro.2014.01.006. Epub 2014 Jan 31.

PMID:
24530273
17.

Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.

Huang KL, Lu WC, Wang YY, Hu GC, Lu CH, Lee WY, Hsu CC.

Aust N Z J Psychiatry. 2014 Jul;48(7):663-71. doi: 10.1177/0004867414525837. Epub 2014 Mar 6.

PMID:
24604920
18.

A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.

Sechter D, Troy S, Paternetti S, Boyer P.

Eur Psychiatry. 1999 Mar;14(1):41-8.

PMID:
10572324
19.

Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.

Fava M, McGrath PJ, Sheu WP; Reboxetine Study Group..

J Clin Psychopharmacol. 2003 Aug;23(4):365-9.

PMID:
12920412
20.

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.

Mao PX, Tang YL, Jiang F, Shu L, Gu X, Li M, Qian M, Ma C, Mitchell PB, Cai ZJ.

Depress Anxiety. 2008;25(1):46-54.

PMID:
17149753

Supplemental Content

Support Center